AbCellera (ABCL) announced that it has expanded its existing collaboration with AbbVie (ABBV) to include the discovery of T-cell engagers in oncology. The expansion builds upon the successful ...

KeyBanc lowered the firm’s price target on AbCellera (ABCL) to $4 from $5 and keeps an Overweight rating on the shares. The firm believes there are several key themes that should play out this ...

The company has a solid financial foundation, maintaining $700 million in cash and short-term investments with virtually no debt. AbCellera is further supported by $225 million in government ...

We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Source: AbCellera Biologics Inc. The views and opinions expressed herein are the ...

AbCellera (Nasdaq: ABCL ... in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required ...

The company has a solid financial foundation, maintaining $700 million in cash and short-term investments with virtually no debt. AbCellera is further supported by $225 million in government grants ...

AbCellera is expanding its collaboration with pharmaceutical company AbbVie to include the discovery of T-cell engagers in oncology. The new agreement will see the Canadian developer of antibody ...

Inquiries Media: Tiffany Chiu; [email protected], +1(236)521-6774 ... represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any ...

VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL ... statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking ...

VANCOUVER - AbCellera (NASDAQ:ABCL) has announced the expansion of its partnership with pharmaceutical giant AbbVie Inc . (NYSE:ABBV), a prominent player in the biotechnology industry with a ...